The platform relies on patient-derived organoids, three-dimensional clusters of tumor cells grown in a supportive gel that recapitulate key architectural and molecular features of the original cancer. Organoids have generated enormous enthusiasm in precision oncology because they allow clinicians to screen multiple drugs against a living surrogate of a patient’s tumor before committing that patient to a regimen. Yet the conventional route to building them, which begins with surgically resected or biopsied tissue, carries substantial drawbacks. Tissue acquisition is invasive, often requires a procedure that may not be clinically justified, and yields samples with low tumor cellularity. The resulting cultures can be contaminated with stromal and immune cells that dilute the tumor-specific signal, and establishment rates for pancreatic cancer organoids have historically been frustratingly low.

The Yonsei University team, led by researchers from the Division of Gastroenterology in collaboration with the Departments of Pathology and Hepatobiliary and Pancreatic Surgery at Severance Hospital, took a different route entirely. Rather than solid tissue, they started with malignant effusions, the pleural fluid that accumulates around the lungs and the ascitic fluid that pools in the abdomen of patients with advanced pancreatic ductal adenocarcinoma. These fluids are collected routinely for symptom management through minimally invasive drainage procedures, meaning that the raw material for organoid culture is essentially a clinical byproduct. Because the fluid already contains free-floating tumor cells shed from metastatic deposits, the researchers reasoned that it could serve as a rich, relatively pure starting inoculum.

Their reasoning proved correct. Fluid-derived organoids, or FDOs, established from these effusions grew faster than organoids generated from matched tissue samples, showed a higher establishment success rate, and carried markedly less non-tumor contamination. The comparison was not simply a matter of convenience. The team performed extensive quality control to demonstrate that FDOs faithfully mirror the biology of the parental tumors. Histopathological examination of hematoxylin and eosin stained sections showed that the organoids retained the glandular architecture characteristic of pancreatic ductal adenocarcinoma. Immunostaining for cytokeratin 7, an epithelial marker expressed in pancreatic ductal cells, confirmed ductal origin. Critically, mutation analysis confirmed that the organoids carried the same KRAS driver mutations as the original tumors. Since activating mutations in KRAS, most commonly at codon 12, occur in the vast majority of pancreatic cancers and anchor much of the field’s targeted drug development, this genetic concordance is essential for the model to have any translational value.

To characterize organoid morphology and drug response in fine detail without destructive processing, the researchers turned to holotomography, a label-free imaging technique that uses coherent light to reconstruct three-dimensional refractive index maps of living cells. This allowed quantitative measurement of cellular and organoid morphology and of how the structures changed in response to drug exposure, complementing conventional viability assays.

One of the most clinically significant demonstrations involved MRTX1133, a selective inhibitor of the KRAS G12D mutant protein. KRAS G12D is among the most common KRAS variants in pancreatic cancer, and MRTX1133 has emerged as a preclinical benchmark for direct KRAS targeting in this tumor type. In the study, FDOs harboring the KRAS G12D mutation showed marked sensitivity to the inhibitor, confirming that the fluid-derived platform can reproduce the drug-response behavior expected of a genetically defined tumor. The result establishes a proof of concept that FDOs can serve as a rapid and scalable test bed for emerging targeted agents, potentially shortening the path from genetic diagnosis to an individualized treatment decision.

The second major contribution of the study goes beyond the platform itself and into the molecular roots of chemotherapy failure. Gemcitabine, a nucleoside analog that has anchored pancreatic cancer chemotherapy for years, frequently stops working as tumors evolve resistance. To understand why, the team performed transcriptomic profiling, comparing gene expression in FDOs that responded to chemotherapy with expression in those that did not. Gene set enrichment and differential expression analysis converged on three genes that were consistently upregulated in the resistant cultures: CEMIP, which encodes cell migration inducing hyaluronidase 1; CALB2, which encodes calbindin 2, also known as the heart and neural crest derivatives expressed protein; and LY6D, a member of the lymphocyte antigen 6 family of glycosylphosphatidylinositol-anchored cell surface proteins.

Expression alone does not prove causation, so the researchers moved to functional validation. When they manipulated the activity of these genes in pancreatic cancer cell lines, the results were unambiguous: elevated CEMIP, CALB2, and LY6D suppressed apoptosis, the programmed cell death pathway that gemcitabine is designed to trigger, and thereby conferred resistance to the drug. CEMIP in particular has been previously implicated in hyaluronic acid metabolism and epithelial-mesenchymal transition, processes that pancreatic tumors exploit to remodel their microenvironment and escape cytotoxic stress. The new findings place all three genes squarely in the mechanistic chain linking cellular stress to survival.

The clinical implications of the three-gene signature were reinforced by outcome data. In analyses of patient cohorts, high expression of the CEMIP, CALB2, and LY6D signature correlated with worse progression-free survival and worse overall survival, indicating that the same genes that protect organoids from gemcitabine in a dish are associated with poorer outcomes in patients. This dual role, as both a mechanistic driver and a prognostic marker, is what gives the finding its translational weight. A test measuring the three-gene signature could in principle identify patients unlikely to benefit from standard chemotherapy, steering them toward alternative regimens or clinical trials of targeted and resistance-overcoming strategies. The genes themselves also represent candidate therapeutic targets, since interfering with their activity might restore sensitivity to apoptosis-inducing drugs.

The work also carries broader implications for how organoid models are built across oncology. Effusions are not unique to pancreatic cancer; malignant pleural and peritoneal effusions arise in ovarian, gastric, lung, and breast cancers, among others. A methodology that converts a routine drainage procedure into a high-fidelity drug-screening platform within days rather than weeks could be adapted widely, particularly for patients with advanced disease for whom tissue biopsy is impractical or unsafe. The scalability of the approach addresses one of the persistent bottlenecks of precision oncology: the sheer logistics of generating a personalized model quickly enough for it to influence a treatment decision made under time pressure.

The study was conducted under ethical approval from the Institutional Review Board of Yonsei University with written informed consent from all patients, and it was supported by grants from the National Research Foundation of Korea and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute. The research article was published as an accepted, citable open-access version carrying a permanent digital object identifier, with the final version of record to follow.

Taken together, the findings advance pancreatic cancer research on two fronts simultaneously. They provide a minimally invasive, rapid, and genetically faithful organoid platform derived from malignant effusions, validated against a state-of-the-art KRAS targeted inhibitor. And they expose a concrete molecular mechanism of chemotherapy resistance, distilled into a three-gene signature with demonstrated prognostic power. For a disease in which treatment options remain scarce and clinical timelines are unforgiving, tools that accelerate both drug selection and biomarker discovery are welcome indeed. The next steps, which the researchers and the field more broadly will be watching closely, involve prospective validation of the gene signature in larger patient cohorts and exploration of whether targeting CEMIP, CALB2, or LY6D can resensitize resistant tumors to gemcitabine and other cytotoxic agents.

The innovative method described in this study builds on previous successes with human induced pluripotent stem cell-derived cancer organoids but extends and optimizes these principles for use with primary tumor specimens from children. Unlike existing models, which often rely on established cell lines or animal models that fail to faithfully replicate human tumor characteristics, these newly developed patient-derived tumoroids maintain the diverse cellular architecture and molecular landscape of their original tumors. Such fidelity is critical for deciphering the intricate disease mechanisms and tailoring effective treatment strategies.

Generating these complex tumoroids involves a carefully optimized protocol that spans approximately four weeks from sample acquisition to tumoroid establishment. The researchers have meticulously refined each step—from tissue dissociation, cell culture conditions, to tumoroid amplification—to maximize efficiency and reproducibility. Notably, their protocol facilitates not only the generation but also the long-term biobanking and cryopreservation of tumoroids. This capability is vital for building extensive repositories that researchers worldwide can access, providing a sustainable resource for future studies and drug development.

An exciting dimension of this protocol is its versatility in enabling downstream drug screening applications. Employing a calcein-based live-cell staining method combined with automated image analysis, researchers can perform scalable, low-throughput screening that yields rapid and quantifiable assessments of tumoroid responses to various therapeutic agents. This approach equips scientists with a potent tool to examine drug efficacy and resistance mechanisms directly on patient-derived tumor models, bridging the crucial gap between laboratory research and clinical applicability.

The introduction of pediatric patient-derived xenograft tumoroids (pPDXTs) as an extension of the tumoroid system represents a strategic integration with in vivo modeling. By transplanting tumoroids into immunocompromised mice, researchers can investigate tumor behavior in a living system, offering a complementary platform for preclinical testing. This dual in vitro and in vivo workflow allows for more comprehensive interrogation of tumor biology and therapeutic vulnerabilities, potentiating the discovery of viable treatment regimens.

One of the key challenges addressed by this protocol is the inherent variability and heterogeneity of pediatric brain tumors. Historically, this complexity has impeded the development of universally applicable models and remained a major obstacle in therapeutic advancement. By preserving tumor heterogeneity, these tumoroids promise to revolutionize personalized medicine approaches, enabling patient-specific investigations that reflect individual tumor biology, thus enhancing the potential for tailored, effective therapies.

Beyond technical innovation, the protocol emphasizes scalability and accessibility, which are critical for widespread adoption across neuroscience and cancer research communities. It strikes a balance between intricate biological modeling and practical feasibility, facilitating broader use in laboratories that may lack extensive experience with patient-derived samples. The authors note that proficiency typically requires several months of hands-on experience, underscoring the method’s complexity but also its replicability once mastered.

Furthermore, the method’s compatibility with automated imaging and quantitative analysis tools signals a forward-thinking integration with digital pathology and computational biology approaches. These technologies enable high-content phenotypic screening and robust data generation, which are essential for modern drug discovery pipelines. By standardizing tumoroid culture and analysis, this protocol helps reduce experimental variability, enhancing the reliability and impact of research findings.

Importantly, the study points to the profound clinical implications of their work. Pediatric brain tumors remain one of the most challenging fields, with limited treatment options and often devastating prognoses. Incorporating patient-derived tumoroids into preclinical pipelines offers a tangible route to test novel therapeutics rapidly and more accurately predict treatment responses before clinical trials, thereby potentially accelerating the development of safer, more effective therapies for vulnerable pediatric patients.

The detailed methodology also addresses bioethical and logistical considerations associated with working on pediatric tumor samples. The protocol outlines procedures ensuring responsible sample acquisition, handling, and database management, reflecting adherence to regulatory standards and respect for patient privacy. This ethical rigor is increasingly vital as personalized medicine becomes more integrated into research frameworks.

Another remarkable aspect of this work is its interdisciplinary nature, combining expertise from neuro-oncology, stem cell biology, bioengineering, and computational analysis. Such a collaborative approach underscores the complexity of pediatric brain tumor research and the need for multifaceted strategies to overcome persistent challenges. This protocol exemplifies how leveraging diverse scientific domains can yield innovative solutions with considerable translational impact.

The authors also highlight the significance of cryopreservation and biobanking strategies, which allow long-term storage and transport of tumoroids without compromising their biological properties. This feature not only facilitates multicenter collaborations but also reduces reliance on fresh tissue samples, which are often scarce and logistically difficult to obtain. Consequently, the tumoroids have the potential to serve as a renewable resource for ongoing research worldwide.

In summary, the introduction of this comprehensive platform for generating, maintaining, and analyzing pediatric patient-derived tumoroids is a major leap forward in pediatric neuro-oncology. It addresses critical gaps in model availability and opens the door to precision oncology approaches tailored to children suffering from these devastating brain cancers. The scalability and reproducibility of the method ensure it will become a cornerstone for future mechanistic studies and preclinical drug development.

As the research community begins to adopt and refine this protocol, the hope is that it will catalyze a wave of discoveries and innovative treatments, ultimately translating to improved patient outcomes. The ability to model pediatric tumor biology faithfully in vitro and study therapeutic responses in real time marks an exciting era in pediatric cancer research—one poised for rapid therapeutic advancements that could change the clinical landscape forever.

The lasting impact of this methodology will be its contribution to personalized medicine paradigms, enabling clinicians and scientists to predict and optimize treatment strategies at the individual patient level. With further refinement and integration with genomic and molecular profiling, patient-derived tumoroids could become indispensable tools in the fight against pediatric brain tumors, offering new hope to patients, families, and healthcare providers alike.

Subject of Research: Pediatric brain tumors, specifically ependymoma and medulloblastoma, involving the development of patient-derived tumoroid models.

Article Title: Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening.

Article References:
Lago, C., Leva, G., Kool, M. et al. Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01347-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-026-01347-9

The study, published in BioMedical Engineering OnLine, represents a significant stride in cancer modeling by moving away from traditional two-dimensional cultures toward a more physiologically relevant 3D model. The researchers synthesized and characterized three distinct hydrogel formulations to identify the optimal matrix for cultivating GBM cells in a way that mirrors their natural behavior within the brain. Hydrogels, due to their high water content and tunable mechanical properties, are emerging as premier scaffolds for 3D cell cultures, capable of mimicking the extracellular matrix (ECM) stiffness and biochemical cues critical for maintaining tumor cell phenotype and function.

To determine which hydrogel formulation best supported GBM cell growth, the team utilized an array of sophisticated techniques. Rheological measurements provided detailed insights into the mechanical stiffness and viscoelastic properties of each hydrogel, essential features that influence cell behavior in three-dimensional space. Fourier transform infrared spectroscopy (FT-IR) allowed for precise chemical characterization, confirming the successful combination of gelatin and sodium alginate polymers. Additionally, scanning electron microscopy (SEM) helped visualize the hydrogel’s porous architecture, crucial for nutrient diffusion and waste removal in long-term cell cultures.

Among the three hydrogels tested, the formulation containing 5% weight/weight gelatin combined with 5% sodium alginate emerged superior. This specific composition not only exhibited ideal rheological properties that simulate the brain’s soft tissue environment but also supported the highest viability of GBM cells over extended culture periods. Gelatin, rich in bioactive motifs such as Arg-Gly-Asp (RGD) sequences, facilitates cell adhesion and proliferation, while the alginate component enhances structural integrity. This hybrid scaffold successfully maintained the three-dimensional organization of tumor spheroids, a critical advance beyond traditional monolayer cultures.

With the optimal hydrogel platform established, the researchers turned their attention to probing the role of CD73, an extracellular enzyme known to generate adenosine, which promotes immunosuppression and tumor progression. Previous studies have hinted at CD73’s involvement in GBM pathogenesis, but in vitro models capable of reflecting these dynamics were lacking. Using their 3D culture model, the team exposed GBM cell spheroids to a selective CD73 inhibitor to evaluate therapeutic responsiveness.

The results were compelling: CD73 inhibition led to a pronounced reduction in GBM cell proliferation within the hydrogel model. Furthermore, molecular analysis via real-time PCR demonstrated significant downregulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-alpha (HIF1-α), two critical mediators of angiogenesis and hypoxic adaption in tumors. These changes suggest that blocking CD73 disrupts the tumor’s capacity to sustain its microenvironment and promotes vulnerability to treatment.

This 3D culture system marks a paradigm shift in GBM research by enabling the study of tumor biology and drug responses in conditions that faithfully recapitulate in vivo physiology. Traditional 2D cultures fail to reproduce the cellular heterogeneity, spatial architecture, and microenvironmental pressures characteristic of brain tumors. Consequently, drug responses observed in 2D often lack translational relevance. The hydrogel-based model’s success underscores the importance of biomechanical and biochemical cues in cancer modeling, improving the predictability of preclinical findings.

Importantly, the study’s hydrogel scaffold can be adapted to incorporate additional ECM components or to co-culture GBM cells with stromal and immune cells, opening avenues for even more complex and realistic tumor models. This versatility is critical in the context of GBM, where interactions between cancer cells and the surrounding stroma, including immune cells, play vital roles in tumor progression and resistance to therapy.

Moreover, the findings highlight CD73 as a promising therapeutic target in GBM treatment regimens. CD73’s enzymatic activity generates extracellular adenosine, which suppresses anti-tumor immune responses and fosters pro-tumorigenic signaling pathways. The observed decrease in VEGF and HIF1-α expression following CD73 inhibition suggests that this approach may impair tumor angiogenesis and adaptation to hypoxic stress, both hallmarks of aggressive GBM. These molecular changes provide mechanistic insights and emphasize the potential benefit of combining CD73 inhibitors with current standards of care, such as radiotherapy and temozolomide chemotherapy.

On a broader scale, this research exemplifies the growing intersection between bioengineering and cancer biology. Material science innovations like engineered hydrogels are vital tools enabling the recreation of complex tumor microenvironments in vitro. By combining material characterization techniques (rheology, FT-IR, SEM) with molecular and cellular assays, the study offers a holistic approach that bridges the gap between laboratory models and clinical realities, fostering the translation of bench discoveries into tangible cancer therapies.

The implications of this work extend beyond glioblastoma. Hydrogel-based 3D cultures could be customized for other solid tumors where microenvironmental factors dictate therapeutic sensitivities. Personalized medicine applications also become feasible, where patient-derived tumor cells can be cultured in hydrogels that simulate their native environment, allowing rapid screening of therapeutic compounds and personalized treatment strategies.

In sum, the development of this hydrogel-based 3D culture system is a critical advance in GBM research, providing a robust and versatile platform that captures tumor complexity and facilitates the study of targeted therapies such as CD73 inhibitors. The combination of precise material engineering and rigorous biological validation heralds a new era where cancer treatment development is informed by more physiologically relevant models, promising improved outcomes for patients with this devastating disease.

As ongoing research continues to refine and expand upon these findings, it is anticipated that hydrogel-based 3D culture systems will become foundational in preclinical oncology research, accelerating drug discovery pipelines and enhancing the predictive power of experimental cancer models. The study offers renewed hope that integrating bioengineering and molecular targeting can unlock new strategies to overcome the formidable barriers in glioblastoma therapy.

Subject of Research: Glioblastoma multiforme cell culture models and therapeutic response to CD73 inhibition using hydrogel-based 3D systems.

Article Title: Development of a hydrogel-based three-dimensional (3D) glioblastoma cell lines culture as a model system for CD73 inhibitor response study.

Article References:
Bahraminasab, M., Asgharzade, S., Doostmohamadi, A. et al. Development of a hydrogel-based three-dimensional (3D) glioblastoma cell lines culture as a model system for CD73 inhibitor response study. BioMed Eng OnLine 23, 127 (2024). https://doi.org/10.1186/s12938-024-01320-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12938-024-01320-1